Connect with us

Health

Phico Therapeutics awarded up to $18.2 million USD (c.£13.2 million GBP) CARB-X funding to advance SASPject antibacterial therapy through Phase 1 clinical trials – News-Medical.net

Phico Therapeutics has been awarded a grant of up to $18.2 million USD to tackle the global rising threat of drug-resistant bacteria.

Published

on

Article feature image

Phico Therapeutics Ltd (‘Phico’), a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, has been awarded a grant of up to $18.2 million USD (circa. £13.2 million GBP) from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
Phico Therapeutics…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Mediterranean diet may prevent memory loss and dementia, study finds – 9Coach
Article feature image
Embryo gene editing in IVF can have potential major impacts on humanity – News-Medical.Net